EUCTR2010-022235-10-DE
Active, not recruiting
Phase 1
A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with newly diagnosed or relapsed high-grade pediatric MDS or JMML - Azacitidine in high grade MDS and JMML pediatric patients
Drugsvidaza
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Erasmus MC
- Enrollment
- 65
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •In this study 4 subgroups of patients are eligible, which will be enrolled in 4 different strata:
- •stratum 1: newly diagnosed patients with advanced MDS (RAEB or RAEB\-t) in a ‘pre stem cell transplantation window’.
- •stratum 2: relapsed patients with advanced MDS in a ‘re\-transplantation window’. At relapse azacitidine may also be continued when a 2nd transplant is not feasible, as long as the patient benefits from treatment.
- •stratum 3: newly diagnosed patients with JMML in a ‘pre\-stem cell transplantation window’.
- •stratum 4: relapsed patients with JMML in a ‘re\-transplantation window’. Azacitidine may also be continued when a 2nd transplant is not feasible and as long as the patient benefits from treatment.
- •straum 5:newly diagnosed or relapsed patients with secondary advanced MDS, occurring after
- •chemotherapy, radiotherapy and or stem\-cell transplantation, or secondary cases after
- •prior treatment for aplastic anemia. Note: secondary MDS cases after bone\-marrow failures or familial cases are not eligible
- •General conditions:
- •Advanced primary or secondary MDS or JMML confirmed by the diagnostic criteria as specified in the EWOG\-MDS 2006 protocol (see appendix 1\)
Exclusion Criteria
- •Prior or current history:
- •Other serious illnesses or medical conditions
- •Genetic abnormalities indicative of AML
- •JMML patients in whom a diagnosis of Noonan syndrome is suspected based on clinical history and/or presenting symptoms
- •Patients with secondary MDS with underlying bone\-marrow failure syndromes or with familial MDS
- •Isolated extramedullary disease
- •Symptomatic CNS\-involvement
- •Current uncontrolled infection
- •Cardiac toxicity (shortening fraction below 28%)
- •Concurrent treatment with any other anti\-cancer therapy is not allowed
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Azacitidine in children with MDS or JMMAdvanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)MedDRA version: 15.1Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 15.1Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2010-022235-10-ITErasmus MC65
Active, not recruiting
Phase 1
Azacitidine in children with MDS or JMMAdvanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)MedDRA version: 17.1Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2010-022235-10-ESErasmus MC5
Active, not recruiting
Phase 1
Azacitidine in children with MDS or JMMEUCTR2010-022235-10-DKErasmus MC65
Recruiting
Phase 2
A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMMMDS and JMML10018865NL-OMON47695Erasmus MC, Universitair Medisch Centrum Rotterdam3
Active, not recruiting
Phase 1
Azacitidine in children with MDS or JMMRelapsed advanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)MedDRA version: 20.0Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2010-022235-10-NLErasmus MC24